WVEN-531 is under clinical development by Wave Life Sciences and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how WVEN-531’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WVEN-531 overview
WVEN-531 is under development for the treatment of Duchenne muscular dystrophy. The drug candidate is a phosphoryl guanidine-modified stereopure splicing antisense oligonucleotide against DMD mRNA inducing exon 53 skipping. It is administered through intravenous route. It is being developed based on PRISM platform which is chemistry platform, it utilizes phosphorothioate (PS) modification of nucleic acid therapeutics.
Wave Life Sciences overview
Wave Life Sciences discovers, develops, and commercializes medicines for genetic diseases. The company’s pipeline consists of WVE-006 for Alpha-1 antitrypsin deficiency (AATD), WVE-N531 for Duchenne muscular dystrophy (DMD), WVE-003 for Huntington’s disease (HD) and INHBE for Obesity and other metabolic disorders. The company employs its proprietary chemistry platform PRISM, to design, optimize and manufacture stereo pure oligonucleotides with improved safety, tolerability and efficacy compared to that of stereorandom oligonucleotides. Wave Life Sciences is jointly advancing its CNS pipeline candidates in collaboration with Takeda. It has operations in Singapore, the US, Japan, the UK, and Ireland. Wave Life Sciences is headquartered in Singapore City, Singapore.
For a complete picture of WVEN-531’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
